John F. Seymour
Peter MacCallum Cancer Centre
781 Papers
5.1K Citations
John F. Seymour is an academic researcher from Peter MacCallum Cancer Centre. The author has contributed to research in topics: Medicine & Rituximab. The author has an hindex of 96, co-authored 706 publications. Previous affiliations of John F. Seymour include Royal Children's Hospital & St. Vincent's Health System.
Chat about Author
Papers
Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab.
Glen A Kennedy,John F. Seymour,Max Wolf,Henry Januszewicz,Jill Davison,Christopher McCormack,Gail Ryan,Henry Miles Prince +7 more
TL;DR: A phase II study to evaluate the safety, tolerability and efficacy of alemtuzumab in patients with relapsed or refractory advanced stage cutaneous T‐cell lymphoma.
150
Long-Term Follow-Up of a Prospective Study of Combined Modality Therapy for Stage I–II Indolent Non-Hodgkin’s Lymphoma
John F. Seymour,Barbara Pro,Lillian M. Fuller,John T. Manning,Fredrick B. Hagemeister,Jorge E. Romaguera,Maria Alma Rodriguez,Chul S. Ha,Terry L. Smith,Ana Ayala,Mark A. Hess,James D. Cox,Fernando Cabanillas,Peter McLaughlin +13 more
TL;DR: With prolonged follow-up, combined-modality therapy with risk-adapted COP-/CHOP-Bleo and IF radiation has attained higher rates of disease control and survival than previously reported with IF-XRT alone.
146
BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria.
Susan Branford,John F. Seymour,Andrew Grigg,Christopher Arthur,Zbigniew Rudzki,Kevin Lynch,Timothy P. Hughes +6 more
TL;DR: With prolonged therapy, BCR-ABL continued to decline in most patients and undetectable BCR -ABL was no longer a rare event.
146
Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Umberto Vitolo,John F. Seymour,Maurizio Martelli,Gerald Illerhaus,Timothy M Illidge,Emanuele Zucca,Elias Campo,M. Ladetto +7 more
TL;DR: * Hematology, University-Hospital Città della Salute e della Scienza, Torino, Italy; Peter MacCallum Cancer Centre, and University of Melbourne, Melbourne, Australia; Department of Cellular Biotechnologies and Hematologists, University ‘Sapienza’, Rome, Italy.
141
Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma.
Maher K. Gandhi,Eleanore Lambley,Jacqueline M. Burrows,Ujjwal Dua,Suzanne L. Elliott,Peter J. Shaw,H. Miles Prince,Max Wolf,Kerrie Clarke,Craig Underhill,Tony Mills,Peter Mollee,Devinder Gill,Paula Marlton,John F. Seymour,Rajiv Khanna +15 more
TL;DR: It is shown that free plasma EBV-DNA has excellent sensitivity and specificity, and can be used as a noninvasive biomarker forEBV-positive HL and that serial monitoring could predict response to therapy.
140